Immunotherapy Drugs Market by Type (Monoclonal Antibodies, Check Point Inhibitors, Interferons, and Interleukins), Therapy Area (Cancer, Autoimmune diseases& Inflammatory, Infectious Diseases), End User (Hospitals, Clinics ) - Global Forecast to 2025

免疫療法薬の世界市場予測(~2025):種類別、セラピーエリア別、エンドユーザー別

◆タイトル:Immunotherapy Drugs Market by Type (Monoclonal Antibodies, Check Point Inhibitors, Interferons, and Interleukins), Therapy Area (Cancer, Autoimmune diseases& Inflammatory, Infectious Diseases), End User (Hospitals, Clinics ) - Global Forecast to 2025
◆商品コード:PH 3926
◆調査・発行会社:MarketsandMarkets
◆発行日:2020年5月29日
◆ページ数:177
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥529,650見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥711,550見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥872,050見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarkets社は免疫療法薬の世界市場が2020年1,630億ドルから2025年2,746億ドルまで、年平均11.0%成長すると見込んでいます。本調査レポートでは、免疫療法薬の世界市場を詳細に調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、種類別(モノクローナル抗体、チェックポイント阻害剤、インターフェロン&インターロイキン、その他免疫療法)分析、治療領域別分析、エンドユーザー別分析、地域別分析、競争状況、企業概要などを含め、提供しております。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・免疫療法薬の世界市場規模:種類別(モノクローナル抗体、チェックポイント阻害剤、インターフェロン&インターロイキン、その他免疫療法)
・免疫療法薬の世界市場規模:治療領域別
・免疫療法薬の世界市場規模:エンドユーザー別
・免疫療法薬の世界市場規模:地域別
・競争状況
・企業概要

“The immunotherapy drugs market is projected to grow at a CAGR of 11.0% during the forecast period (2020–2025).”
The global immunotherapy drugs market is projected to reach USD 274.6 billion by 2025 from USD 163.0 billion in 2020, at a CAGR of 11.0 % during the forecast period. Market growth is primarily driven by the rising demand for immunotherapies over conventional treatments and a growing prevalence of target indications. However, timeline issues, side-effects, and manufacturing complexities are expected to restrict market growth to a certain extent.

“Monoclonal antibodies are expected to witness high demand during the forecast period.”
The adoption of immunotherapy in cancer has been rising in recent years due to the introduction of safe and efficient treatments. Monoclonal antibodies are immunoglobulins derived by cultivating immune cells in the lab to target specific antigens present on the surface of cancer cells. These antibodies, when used as a therapy, attach themselves to cancer/abnormal cells and mark them for destruction by the body’s natural immune system. Monoclonal antibodies hold the largest share of the immunotherapy drugs market owing to their high specificity and few side-effects.

“Cancer is one of the key application areas for immunotherapies.”
On the basis of the therapeutic area, the immunotherapy drugs market is segmented into cancer, autoimmune & inflammatory diseases, infectious diseases, and others. Cancer accounted for the largest share of the immunotherapy drugs market in 2019. This is mainly due to the large number of approvals, rising prevalence of cancer, and growing research activity in this area, among other factors.

“By end user, hospitals accounted for the largest share of the immunotherapy drugs market in 2019.”
On the basis of the end user, the global immunotherapy drugs market is segmented into hospitals, clinics, and other end users. Hospitals accounted for the largest share of the immunotherapy drugs market in 2019, mainly due to their high spending on immunotherapies and the availability of the necessary infrastructure and facilities to provide advanced treatments.

“The market in North America is projected to hold the largest share of the global immunotherapy drugs market.”
North America is projected to dominate the market during the forecast period. This can be attributed to factors such as the rising prevalence of cancer and increasing initiatives by industry players. On the other hand, the Asia Pacific region is expected to grow at the highest CAGR of 11.9% during the forecast period due to factors such as aggressive investments by key market players and the increase in government spending on healthcare.


A breakdown of the primary participants referred to for this report is provided below:
• By Company Type (Supply-side): Tier 1: 29%, Tier 2: 37%, and Tier 3: 34%
• By Category (Demand-side): Pharmaceutical & Biotechnology Companies: 55%, Hospitals and Reference Laboratories: 35%, and Academic & Research Institutes: 10%
• By Designation: C-level: 35%, Director level: 25%, and Managers: 40%
• By Region: North America: 35%, Europe: 32%, Asia: 22%, and the RoW: 11%

F. Hoffmann-La Roche Ltd. (UK), Pfizer Inc. (US), and Merck & Co (US) are the key players operating in the immunotherapy drugs market. Others include Novartis International AG (UK), Johnson & Johnson (US), Sanofi (France), GlaxoSmithKline Plc (UK), Amgen Inc. (US), AbbVie Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca (UK), and Immatics Biotechnologies (Germany).

Research Coverage:
The report analyzes the immunotherapy drugs market and aims at estimating the market size and future growth potential of this market based on various segments such as product, type, application, end user, and region. The report also includes competitive analyses of the key players in this market, along with their company profiles, product and service offerings, recent developments, and key market strategies.

Reasons to Buy the Report
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one, or a combination of the below-mentioned five strategies.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on the product portfolios of the top players in the immunotherapy drugs market. The report analyzes the market based on type, therapeutic area, end user, and region
• Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the immunotherapy drugs market
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of immunotherapy drugs solutions across regions
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the immunotherapy drugs market
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the immunotherapy drugs market

【レポートの目次】

1 INTRODUCTION (Page No. – 16)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET SCOPE
1.2.1 MARKETS COVERED
1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. – 19)
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Breakdown of primary sources
2.2 MARKET SIZE ESTIMATION
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 MARKET SHARE ESTIMATION
2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. – 28)

4 PREMIUM INSIGHTS (Page No. – 31)
4.1 IMMUNOTHERAPY DRUGS MARKET OVERVIEW
4.2 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE (2019)
4.3 GEOGRAPHIC SNAPSHOT OF THE IMMUNOTHERAPY DRUGS MARKET
4.4 PIPELINE OF PHASE 2/3 IMMUNOTHERAPY DRUGS

5 MARKET OVERVIEW (Page No. – 42)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing adoption of immunotherapy drugs over conventional treatment regimens
5.2.1.2 Rising prevalence of cancer and autoimmune & infectious diseases
5.2.1.3 Increasing demand for monoclonal antibodies and biosimilars
5.2.2 RESTRAINTS
5.2.2.1 Timeline issues, side-effects, and manufacturing complexities
5.2.2.2 High attrition rate in the product development cycle
5.2.3 OPPORTUNITIES
5.2.3.1 Increased demand for personalized medicines
5.2.3.2 High scope for growth in emerging economies
5.2.3.3 Development of affordable nanoparticles for deploying immunotherapies
5.2.4 CHALLENGES
5.2.4.1 High cost of immunotherapy treatment, regional disparities, and lack of insurance coverage
5.2.4.2 Side-effects and low efficacy of immunotherapy drugs
5.2.4.3 Lack of awareness
5.2.4.4 Delays in diagnosis and treatment
5.2.5 IMPACT OF THE COVID-19 PANDEMIC ON THE IMMUNOTHERAPY DRUGS MARKET

6 IMMUNOTHERAPY DRUGS MARKET, BY TYPE (Page No. – 51)
6.1 INTRODUCTION
6.2 MONOCLONAL ANTIBODIES
6.2.1 MONOCLONAL ANTIBODIES ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2019
6.3 CHECKPOINT INHIBITORS
6.3.1 CHECKPOINT INHIBITORS MARKET TO GROW OWING TO THEIR WIDE APPLICABILITY IN NUMEROUS CANCER TREATMENTS
6.4 INTERFERONS & INTERLEUKINS
6.4.1 INTERFERONS & INTERLEUKINS USE THE PATIENT’S IMMUNE SYSTEM, WHICH PROVIDES SIGNIFICANT BENEFITS
6.5 OTHER IMMUNOTHERAPIES

7 IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA (Page No. – 57)
7.1 INTRODUCTION
7.2 CANCER
7.2.1 MALIGNANT CANCERS
7.2.1.1 Malignant cancers held the largest share of the immunotherapy drugs market in 2019
7.2.2 BENIGN CANCERS
7.2.2.1 Availability of a range of drugs for benign cancer treatment supports market growth
7.3 AUTOIMMUNE & INFLAMMATORY DISEASES
7.3.1 STRONG DEMAND FOR IMMUNOTHERAPIES BOLSTERS MARKET GROWTH IN THIS SEGMENT
7.4 INFECTIOUS DISEASES
7.4.1 INCREASING PREVALENCE AND RISE IN R&D SUPPORT MARKET GROWTH
7.5 OTHER THERAPEUTIC AREAS

8 IMMUNOTHERAPY DRUGS MARKET, BY END USER (Page No. – 64)
8.1 INTRODUCTION
8.2 HOSPITALS
8.2.1 HOSPITALS ACCOUNTED FOR THE LARGEST SHARE OF THE IMMUNOTHERAPY DRUGS MARKET
8.3 CLINICS
8.3.1 CLINICS PROVIDE FOCUSED, PRIMARY-LEVEL CARE FOR PATIENTS AND CANNOT PROVIDE ADVANCED TREATMENTS
8.4 OTHER END USERS

9 IMMUNOTHERAPY DRUGS MARKET, BY REGION (Page No. – 68)
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 US
9.2.1.1 US holds the largest share of the North American market
9.2.2 CANADA
9.2.2.1 Increasing prevalence of cancer and the growing availability of approved immunotherapy drugs to drive market growth
9.3 EUROPE
9.3.1 UK
9.3.1.1 The UK accounts for the largest share of the European market
9.3.2 GERMANY
9.3.2.1 New law for biosimilars in Germany to drive market growth
9.3.3 FRANCE
9.3.3.1 Initiatives by leading pharma players to drive the French market for immunotherapy drugs
9.3.4 ITALY
9.3.4.1 Availability of reimbursement drives the market in Italy
9.3.5 SPAIN
9.3.5.1 Increasing incidences of cancer to drive market growth during the forecast period
9.3.6 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 CHINA
9.4.1.1 Rising prevalence of cancer and other infectious diseases to boost the adoption of immunotherapy in China
9.4.2 JAPAN
9.4.2.1 Universal health coverage boosts the market for immunotherapy drugs in Japan
9.4.3 INDIA
9.4.3.1 High number of cancer specialty care hospitals to support market growth
9.4.4 AUSTRALIA
9.4.4.1 Government initiatives to pave the way for the development of the Australian immunotherapy drugs market
9.4.5 REST OF ASIA PACIFIC
9.5 REST OF THE WORLD
9.5.1 MIDDLE EAST & AFRICA
9.5.1.1 Infrastructural growth and favorable socioeconomic trends will support market growth in the MEA
9.5.2 BRAZIL
9.5.2.1 Government support and player interest in Brazil will drive the market
9.5.3 REST OF LATIN AMERICA

10 COMPETITIVE LANDSCAPE (Page No. – 109)
10.1 INTRODUCTION
10.2 MARKET EVALUATION FRAMEWORK
10.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS
10.4 COMPETITIVE LEADERSHIP MAPPING (OVERALL MARKET) (2019)
10.4.1 STARS
10.4.2 EMERGING LEADERS
10.4.3 PERVASIVE COMPANIES
10.4.4 EMERGING COMPANIES
10.5 COMPETITIVE SCENARIO
10.5.1 KEY PARTNERSHIPS AND COLLABORATIONS
10.5.2 KEY PRODUCT LAUNCHES
10.5.3 KEY ACQUISITIONS
10.5.4 KEY EXPANSIONS

11 COMPANY PROFILES (Page No. – 115)
(Business Overview, Products Offered, Recent Developments, MnM View)*
11.1 F. HOFFMANN-LA ROCHE
11.2 PFIZER
11.3 MERCK & CO
11.4 NOVARTIS INTERNATIONAL AG
11.5 JOHNSON & JOHNSON
11.6 SANOFI
11.7 GLAXOSMITHKLINE
11.8 ABBVIE
11.9 AMGEN
11.10 BOEHRINGER INGELHEIM
11.11 ASTRAZENECA
11.12 ELI LILLY AND COMPANY
11.13 IMMATICS BIOTECHNOLOGIES GMBH
11.14 GENMAB
11.15 BIONTECH SE
11.16 GILEAD SCIENCES
11.17 NBE THERAPEUTICS
11.18 TEVA PHARMACEUTICALS
11.19 BAYER AG
11.20 BRISTOL-MYERS SQUIBB
11.21 INCYTE CORPORATION

*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.



★調査レポート[免疫療法薬の世界市場予測(~2025):種類別、セラピーエリア別、エンドユーザー別] ( Immunotherapy Drugs Market by Type (Monoclonal Antibodies, Check Point Inhibitors, Interferons, and Interleukins), Therapy Area (Cancer, Autoimmune diseases& Inflammatory, Infectious Diseases), End User (Hospitals, Clinics ) - Global Forecast to 2025 / PH 3926) 販売に関する免責事項
[免疫療法薬の世界市場予測(~2025):種類別、セラピーエリア別、エンドユーザー別] ( Immunotherapy Drugs Market by Type (Monoclonal Antibodies, Check Point Inhibitors, Interferons, and Interleukins), Therapy Area (Cancer, Autoimmune diseases& Inflammatory, Infectious Diseases), End User (Hospitals, Clinics ) - Global Forecast to 2025 / PH 3926) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆